Research Analyst Reaffirms "Buy" Rating on BAT

BusinessBAT by 2FIRSTS.ai

Nov.20.2023

Research Analyst Reaffirms "Buy" Rating on BAT

Research analysts reaffirmed a "buy" rating on British American Tobacco (LON:BATS) after its stock fell 2p (0.02 USD) to 2,518p (30.92 USD) on Wednesday.

In a research report on Wednesday, analysts reconfirmed their "buy" rating on British American Tobacco (LON:BATS). Shares of BATS declined by 2 pence (0.02 USD) to a price of 2,518 pence (30.92 USD) during midday trading on Wednesday.

References:

[1] Jefferies Financial Group Reaffirms Buy Rating for British American Tobacco (LON:BATS)

Also Read:

[1] BAT Celebrating One Year Anniversary of glo™ Smokeless Product

[2] BAT Russian Division's Ownership Transferred to Abu Dhabi

#Research #British American Tobacco (BAT)

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA CTP Acting Director Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace

At the FDLI Tobacco and Nicotine Policy Conference, FDA CTP Acting Director Bret Koplow spoke in favor of promoting tobacco harm reduction to reduce smoking. He backed a legal marketplace for authorized reduced-risk products, potential expansion of flavored e-cigs, and faster FDA reviews to ensure a strong, regulated market.

Oct.29 by 2FIRSTS.ai

Philippine police seize illegal cigarettes and e-cigarettes worth USD 206,400, arrest four suspects

CIDG-Laguna Provincial Field Unit seizes $200k worth of illegal cigarettes and e-cigarettes, arrests four suspects. PNP vows to continue crackdown.

Nov.28 by 2FIRSTS.ai

EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split

The European Union will abstain from voting at the upcoming 11th session of the WHO Framework Convention on Tobacco Control (COP11) in Geneva, following months of internal disagreement over how to regulate tobacco and nicotine products. The decision marks a rare and public fracture in EU health policy, reportedly driven by the European Commission’s hardline anti-tobacco stance.

Nov.18 by 2FIRSTS.ai

South Korea Plans Unified Regulation for Synthetic and Look-Alike Nicotine Products

South Korea Parliament discusses including "nicotine" in Tobacco Business Act; synthetic nicotine testing method established, awaiting legislation approval.